Biotech News
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
Statistically significant (p
Related news
ORGOOrganogenesis2026-07-27 20:05 EST
Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers
ORGOOrganogenesis2025-11-03 18:10 EST
Organogenesis Applauds CMS’s Significant Step In Payment Reform
Organogenesis
Regenerative Medicine Organogenesis develops and manufactures regenerative-medicine products used to support healing in difficult wounds and surgical procedures. Advanced Wound Care The company's wound-care portfolio includes cellular and tissue-based products, placental-derived products and other biologic matrices used in chronic and...
Recent company news
ORGOOrganogenesis2026-08-06 20:05 EST
Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results
ORGOOrganogenesis2026-07-27 20:05 EST
Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers
ORGOOrganogenesis2026-07-09 11:30 EST
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
ORGOOrganogenesis2026-07-06 20:05 EST
Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis
ORGOOrganogenesis2026-05-07 20:06 EST
Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
Stock data
- Close
- 2.41 USD
- Market cap
- 288.23M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States